Chinese researchers describe new PARP-1 inhibitors for cancer

Dec. 23, 2022

Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified nitrogen-containing heterocyclic compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for Jan 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 22, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...